Early Data Support J&J’s COVID-19 Vaccine Push Into Phase III

Single Dose Promising In Phase I Study

 
• By Andrew McConaghie

Johnson & Johnson has released early data putting its COVID-19 vaccine broadly in line with frontrunners from Pfizer and Moderna, but with key advantage of requiring just one injection.

Johnson_and_Johnson
J&J is planning to include 60,000 volunteers in its Phase III trial, more than any of the other frontrunners.

More from Clinical Trials

More from R&D